A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?
Psychedelic Medicine – February 28, 2024
Source: OpenAlex
Summary
A crucial plea emerges for careful consideration in **psilocybin** **clinical trials**. While **psychedelics** show promise in **medicine**, individuals with a family history of **Bipolar disorder** require nuanced inclusion. Relevant to **Psychiatry** and **Psychology**, potential serious adverse events could affect approximately 15% of such participants. Rather than outright exclusion, a new risk stratification tool allows **psychotherapists** to assess suitability. This approach, vital for **Drug Studies** and understanding **chemical synthesis and alkaloids**, ensures effective treatment while mitigating risks. It contrasts with broader discussions in fields like **Cannabis and Cannabinoid Research**, emphasizing tailored protocols.
Abstract
Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.